Kuwaiti molecular diagnostics firm Genatak has begun offering a targeted hereditary breast cancer panel and exome sequencing services for patients with cancer, undiagnosed genetic disorders, and individuals looking to understand disease risk.
Kuwaiti Firm Launches Breast Cancer Panel, Exome Services; Plans Move into Pre-implantation Dx
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.